rehabРеабилитологияJournal of Medical Rehabilitation2949-58732949-5881IRBIS LLC10.17749/2949-5873/rehabil.2025.58rehab-122Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESЛечебная физкультура при неалкогольной жировой болезни печени: современные подходы и доказательная базаTherapeutic exercise in non-alcoholic fatty liver disease: current approaches and evidence-based effectivenesshttps://orcid.org/0000-0002-9931-4928ЗолозоваЕ. А.ZolozovaE. A.

Золозова Елена Александровна, к.м.н., доцент

ул. Баррикадная, д. 2/1, стр. 1, Москва 125993 

Scopus Author ID: 6504313491  

Elena A. Zolozova, PhD, Assoc. Prof. 

2/1 bldg 1 Barrikadnaya Str., Moscow 125993 

Scopus Author ID: 6504313491 

andrey.alexandrov@ipsom.ruhttps://orcid.org/0000-0002-5042-4886БогачеваТ. Е.BogachevaT. E.

Богачева Татьяна Евгеньевна, к.м.н., доцент  

Шереметевский пр-т, д. 8, Иваново 153012

Scopus Author ID: 57188826213 

Tatiana E. Bogacheva, PhD, Assoc. Prof.

8 Sheremetyevsky Ave., Ivanovo 153012 

Scopus Author ID: 57188826213 

tatiana.boga4iova@yandex.ruhttps://orcid.org/0000-0002-1064-8201ДемидовВ. И.DemidovV. I.

Демидов Вадим Игоревич, к.м.н., доцент

Шереметевский пр-т, д. 8, Иваново 153012

WoS ResearcherID: F-9158-2019

Scopus Author ID: 56806409700  

Vadim I. Demidov, PhD, Assoc. Prof. 

8 Sheremetyevsky Ave., Ivanovo 153012 

WoS ResearcherID: F-9158-2019

Scopus Author ID: 56806409700 

Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Ивановский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияIvanovo State Medical UniversityRussian Federation20250804202633193199Copyright © Золозова Е.А., Богачева Т.Е., Демидов В.И., 20262026Золозова Е.А., Богачева Т.Е., Демидов В.И.Zolozova E.A., Bogacheva T.E., Demidov V.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rehabilitology.com/jour/article/view/122

Развитие медицинской науки и здравоохранения позволяет существенно снизить риски прогрессирования тяжелых патологий печени у пациентов с метаболическими нарушениями. Неалкогольная жировая болезнь печени (НАЖБП) является глобальным вызовом для современной гепатологии и реабилитологии. Наиболее эффективный немедикаментозный метод, с помощью которого достигаются цели регресса стеатоза и улучшения метаболического профиля, – лечебная физическая культура (ЛФК). В обзоре проведен системный анализ эффективности различных режимов физических нагрузок в профилактике, лечении и реабилитации пациентов с НАЖБП. Рассмотрены биомеханические и молекулярные механизмы действия упражнений, обозначены современные техники дозирования аэробных и резистентных нагрузок, а также представлены возможности клинического применения ЛФК в составе комплексной терапии. Особое внимание уделено доказательной базе, основанной на данных рандомизированных контролируемых исследований и метаанализов. 

Advances in medical science and healthcare significantly reduce the risk of severe liver disease progression in patients with metabolic disorders. Currently, non-alcoholic fatty liver disease (NAFLD) represents a global challenge for hepatology and rehabilitation medicine, with therapeutic exercise serving as the most effective non-pharmacological method to achieve steatosis regression and improve the metabolic profile. This literature review provides a systematic effectiveness analysis of various physical activity regimens in the management of NAFLD patients, which encompasses prevention, treatment, and rehabilitation. Molecular and biomechanical mechanisms of exercise, modern techniques for prescribing aerobic and resistance loads, and clinical applications of therapeutic exercise are discussed. Special attention is paid to the evidence base from randomized controlled trials and meta-analyses.

восстановительная медицинанеалкогольная жировая болезнь печенилечебная физкультурафизическая реабилитацияметаболический синдромдоказательная медицинаrehabilitation medicinenon-alcoholic fatty liver diseasetherapeutic exercisephysical rehabilitationmetabolic syndromeevidence-based medicineReferencesYounossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64 (1): 73–84. https://doi.org/10.1002/hep.28431.Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64 (1): 73–84. https://doi.org/10.1002/hep.28431.Eslam M., Newsome P.N., Sarin S.K., et al A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73 (1): 202–9. https://doi.org/10.1016/j.jhep.2020.03.039.Eslam M., Newsome P.N., Sarin S.K., et al A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73 (1): 202–9. https://doi.org/10.1016/j.jhep.2020.03.039.Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65 (8): 1038–48. https://doi.org/10.1016/j.metabol.2015.12.012.Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65 (8): 1038–48. https://doi.org/10.1016/j.metabol.2015.12.012.Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78.e5. https://doi.org/10.1053/j.gastro.2015.04.005.Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149 (2): 367–78.e5. https://doi.org/10.1053/j.gastro.2015.04.005.Zelber-Sagi S., Ratziu V., Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011; 17 (29): 3377–89. https://doi.org/10.3748/wjg.v17.i29.3377.Zelber-Sagi S., Ratziu V., Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011; 17 (29): 3377–89. https://doi.org/10.3748/wjg.v17.i29.3377.Samala N., Tersey S.A., Chalasani N., et al. Molecular mechanisms of nonalcoholic fatty liver disease: potential role for 12-lipoxygenase. J Diabetes Complications. 2017; 31 (11): 1630–7. https://doi.org/10.1016/j.jdiacomp.2017.07.014.Samala N., Tersey S.A., Chalasani N., et al. Molecular mechanisms of nonalcoholic fatty liver disease: potential role for 12-lipoxygenase. J Diabetes Complications. 2017; 31 (11): 1630–7. https://doi.org/10.1016/j.jdiacomp.2017.07.014.Sanders F.W.B., Griffin J.L. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016; 91 (2): 452–68. https://doi.org/10.1111/brv.12178.Sanders F.W.B., Griffin J.L. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016; 91 (2): 452–68. https://doi.org/10.1111/brv.12178.Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010; 52 (2): 774–88. https://doi.org/10.1002/hep.23719.Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010; 52 (2): 774–88. https://doi.org/10.1002/hep.23719.Wree A., Broderick L., Canbay A., et al. From NAFLD to NASH to cirrhosisnew insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10 (11): 627–36. https://doi.org/10.1038/nrgastro.2013.149.Wree A., Broderick L., Canbay A., et al. From NAFLD to NASH to cirrhosisnew insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10 (11): 627–36. https://doi.org/10.1038/nrgastro.2013.149.Marra F., Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018; 68 (2): 280–95. https://doi.org/10.1016/j.jhep.2017.11.014.Marra F., Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018; 68 (2): 280–95. https://doi.org/10.1016/j.jhep.2017.11.014.Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328–57. https://doi.org/10.1002/hep.29367.Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67 (1): 328–57. https://doi.org/10.1002/hep.29367.Bedogni G., Bellentani S., Miglioli L., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006: 6: 33. https://doi.org/10.1186/1471-230X-6-33.Bedogni G., Bellentani S., Miglioli L., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006: 6: 33. https://doi.org/10.1186/1471-230X-6-33.Eddowes P.J., Sasso M., Allison M., et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; 156 (6): 1717–30. https://doi.org/10.1053/j.gastro.2019.01.042.Eddowes P.J., Sasso M., Allison M., et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019; 156 (6): 1717–30. https://doi.org/10.1053/j.gastro.2019.01.042.Wong V.W.S., Adams L.A., de Lédinghen V., et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018; 15 (8): 461–78. https://doi.org/10.1038/s41575-018-0014-9.Wong V.W.S., Adams L.A., de Lédinghen V., et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018; 15 (8): 461–78. https://doi.org/10.1038/s41575-018-0014-9.van der Windt D.J., Sud V., Zhang H., et al. The effects of physical exercise on fatty liver disease. Gene Expr. 2018; 18 (2): 89–101. https://doi.org/10.3727/105221617X15124844266408.van der Windt D.J., Sud V., Zhang H., et al. The effects of physical exercise on fatty liver disease. Gene Expr. 2018; 18 (2): 89–101. https://doi.org/10.3727/105221617X15124844266408.Hallsworth K., Adams L.A. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. 2019; 1 (6): 468–79. https://doi.org/10.1016/j.jhepr.2019.10.008.Hallsworth K., Adams L.A. Lifestyle modification in NAFLD/NASH: facts and figures. JHEP Rep. 2019; 1 (6): 468–79. https://doi.org/10.1016/j.jhepr.2019.10.008.Hashida R., Kawaguchi T., Bekki M., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017; 66 (1): 142–52. https://doi.org/10.1016/j.jhep.2016.08.023.Hashida R., Kawaguchi T., Bekki M., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017; 66 (1): 142–52. https://doi.org/10.1016/j.jhep.2016.08.023.European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64 (6): 1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64 (6): 1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.Loschi T.M., Baccan M.D.T.A., Della Guardia B., et al. Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: a systematic review. World J Hepatol. 2023; 15 (10): 1153–63. https://doi.org/10.4254/wjh.v15.i10.1153.Loschi T.M., Baccan M.D.T.A., Della Guardia B., et al. Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: a systematic review. World J Hepatol. 2023; 15 (10): 1153–63. https://doi.org/10.4254/wjh.v15.i10.1153.Sabag A., Barr L., Armour M., et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022; 107 (3): 862–81. https://doi.org/10.1210/clinem/dgab795.Sabag A., Barr L., Armour M., et al. The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022; 107 (3): 862–81. https://doi.org/10.1210/clinem/dgab795.Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Hepatol. 2012; 57 (1): 157–66. https://doi.org/10.1016/j.jhep.2012.02.023.Keating S.E., Hackett D.A., George J., Johnson N.A. Exercise and non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Hepatol. 2012; 57 (1): 157–66. https://doi.org/10.1016/j.jhep.2012.02.023.

The authors declare that there are no conflicts of interest present.